DOX decreases body mass gain over time in a sub-chronic toxicity model. by Gonçalo C. Pereira (156673)

A possible explanation for a nonlinear decline in populations could be a decrease in active AMP concentration over time due to degradation. by Alexandro Rodríguez-Rojas (326213)

Figure 2. Decrease in contrast with age. by Aurélie Porcheron (385827)

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…This study aimed to derive benchmark concentrations from RNaseq data (transcriptomic points-of-departure; tPOD) from a short-term exposure study with early life stages of rainbow trout (RBT; Oncorhynchus mykiss) using benzo[<i>a</i>]pyrene (B[<i>a</i>]P) as the model compound. tPODs were then calibrated with higher organizational-level responses observed during an extended 28 day exposure period. …”

A Two-Year Randomized Trial of Interventions to Decrease Stress Hormone Vasopressin Production in Patients with Meniere’s Disease—A Pilot Study by Tadashi Kitahara (702040)

“…<div><p>Meniere's disease, a common inner ear condition, has an incidence of 15–50 per 100,000. …”

Average changes in (A) spontaneous AP firing rate, (B) ATP and (C) cAMP by decreasing CaMKII activity with KN-93 (high-3 µmol/L, low-0.5 µmol/L), AIP (high-10 µmol/L, low-2 µmol/L), or decreasing calmodulin activity by W-7 (high-50 µmol/L, low-20 µmol/L). by Yael Yaniv (162548)

FSS rescues homocysteine-caused the decrease of NO production in cultured HUVECs after the application of A23187. by Cathy W. C. Bi (108697)

Heart specific RNase Z variants show a mild decrease in longevity and locomotor response. by Ekaterina Migunova (15909887)

Erratum: Decrease in Incidence of Bronchopulmonary Dysplasia with Erythropoietin Administration in Preterm Infants: A Retrospective Study by Rayjada N. (4272919)

“…<b><i>Objective:</i></b> To determine whether EPO treatment for AOP was associated with a reduced incidence of BPD in premature infants. …”

Introduction of the F region decreases the amount of extracellular PSMs and increases the amount of extracellular FnbA. by Chikara Kaito (230958)

IC₅₀ values (mean ±SD in μM) of <i><i>in vitro</i></i> DPPH-radical scavenging properties vs. ascorbic acid and antiinflammation propensities vs. indomethacin of the tes... by MohammedBashar Al-Qazzan (22439236)

Many plasmalogens decrease upon infection. by Gaelle Boncompain (513910)

“…Note that, globally, plasmalogen content decreased during infection, most notably at the later time point. …”

Consumption of a high-fat diet decreases membrane associated DAT protein in the ventral striatum. by Jackson J. Cone (388757)

Doxorubicin decreases CARP levels in ARVMs. by Billy Chen (169862)

Tyrosine mutation of A30P decreases toxicity in <i>Δyhb1</i>. by Alexandra Kleinknecht (3164265)